{
    "id": 1399,
    "fullName": "CDK4 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CDK4 amplification indicates an increased number of copies of the CDK4 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1019,
        "geneSymbol": "CDK4",
        "terms": [
            "CDK4",
            "CMM3",
            "PSK-J3"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "02/07/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) reduced tumor growth of a xenograft model of liposarcoma with CDK4 amplification (PMID: 24045179).",
            "molecularProfile": {
                "id": 1422,
                "profileName": "CDK4 amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 828,
                    "pubMedId": 24045179,
                    "title": "Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24045179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2287,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Ibrance (palbociclib) improved median progression free survival of liposarcoma patients with CDK4 amplification (PMID: 23569315).",
            "molecularProfile": {
                "id": 1422,
                "profileName": "CDK4 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2967,
                    "pubMedId": 23569315,
                    "title": "Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23569315"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alvocidib (flavopiridol) in combination with Adriamycin (doxorubicin) inhibited tumor growth in liposarcoma cell line xenograft models with CDK4 amplification (PMID: 22374332).",
            "molecularProfile": {
                "id": 1422,
                "profileName": "CDK4 amp"
            },
            "therapy": {
                "id": 4646,
                "therapyName": "Alvocidib + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2892,
                    "pubMedId": 22374332,
                    "title": "The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22374332"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21291,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CDK4 amplification were sensitive to Ibrance (palbociclib), demonstrating tumor growth inhibition and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 1422,
                "profileName": "CDK4 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1682,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Ibrance (palbociclib) demonstrated efficacy and improved progression free survival in patients with CDK4 amplified liposarcoma with expression of RB1 (PMID: 23569312).",
            "molecularProfile": {
                "id": 16567,
                "profileName": "CDK4 amp RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5693,
                "name": "adult liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1787,
                    "pubMedId": 23569312,
                    "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23569312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19400,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 16567,
                "profileName": "CDK4 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8417,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AT7519 in patient derived acral lentigineous melanoma cells co-harboring CDK4 amplification and loss of CDKN2A resulted in inhibition of cell proliferation in culture and suppression of tumor growth in the patient derived xenograft models (J Clin Oncol 34, 2016 (suppl; abstr 9512)).",
            "molecularProfile": {
                "id": 26316,
                "profileName": "CDK4 amp CDKN2A loss"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6643,
                    "pubMedId": null,
                    "title": "Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy",
                    "url": "http://meetinglibrary.asco.org/content/167622-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9363,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cell lines harboring CDK4 amplification and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26832,
                "profileName": "CDK4 amp CDKN2A pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma that harbored CDK4 amplification and MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in new brain metastasis and clinical progression 1.5 months after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 28174,
                "profileName": "CDK4 amp MDM2 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C and CDK4 amplification in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34662,
                "profileName": "CDK4 amp KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1422,
            "profileName": "CDK4 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 5014,
                    "name": "CDK Inhibitor (Pan)",
                    "profileName": "CDK4 amp"
                },
                {
                    "id": 5013,
                    "name": "CDK4 Inhibitor",
                    "profileName": "CDK4 amp"
                },
                {
                    "id": 5015,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CDK4 amp"
                }
            ]
        },
        {
            "id": 16567,
            "profileName": "CDK4 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26316,
            "profileName": "CDK4 amp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26832,
            "profileName": "CDK4 amp CDKN2A pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28174,
            "profileName": "CDK4 amp MDM2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34662,
            "profileName": "CDK4 amp KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}